Skip to main content

Advertisement

Log in

Autosomal Dominant Hyper IgE Syndrome – Treatment Strategies and Clinical Outcomes

  • Letter to Editor
  • Published:
Journal of Clinical Immunology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Freeman AF, Holland SM. Clinical manifestations, etiology, and pathogenesis of the hyper-IgE syndromes. Pediatr Res. 2009;65:32R–7R.

    Article  PubMed Central  PubMed  Google Scholar 

  2. Holland SM, DeLeo FR, Elloumi HZ, Hsu AP, Uzel G, Brodsky N, et al. STAT3 mutations in the hyper-IgE syndrome. N Engl J Med. 2007;357(16):1608–19.

    Article  CAS  PubMed  Google Scholar 

  3. Minegishi Y, Saito M, Tsuchiya S. Dominant-negative mutations in the DNA-binding domain of STAT3 cause hyper-IgE syndrome. Nature. 2007;448:1058–62.

    Article  CAS  PubMed  Google Scholar 

  4. Patel NC, Gallagher JL, Torgerson TR, Gilman AL. Successful haploidentical donor hematopoietic stem cell transplant and restoration of STAT3 function in an adolescent with autosomal dominant hyper-IgE syndrome. J Clin Immunol. 2015;35(5):479–85.

    Article  CAS  PubMed  Google Scholar 

  5. Chandesris MO, Melki I, Natividad A, Puel A, Fieschi C, Yun L, et al. Autosomal dominant STAT3 deficiency and hyper-IgE syndrome: molecular, cellular, and clinical features from a French national survey. Medicine. 2012;91:e1–e19.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Andrew R. Gennery.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Flinn, A.M., Cant, A., Leahy, T.R. et al. Autosomal Dominant Hyper IgE Syndrome – Treatment Strategies and Clinical Outcomes. J Clin Immunol 36, 107–109 (2016). https://doi.org/10.1007/s10875-015-0231-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10875-015-0231-8

Keywords

Navigation